Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection

被引:10
|
作者
Armstrong, Emily A. [1 ]
Beal, Eliza W. [2 ]
Shah, Manisha [3 ]
Konda, Bhavana [3 ]
Abdel-Misih, Sherif [2 ]
Ejaz, Aslam [2 ]
Dillhoff, Mary E. [2 ]
Pawlik, Timothy M. [2 ]
Cloyd, Jordan M. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Surg, Div Surg Oncol, Columbus, OH 43210 USA
[3] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
关键词
Neuroendocrine tumor (NET); carcinoid; hepatectomy; radiomics; prognosis; PROGNOSTIC-FACTORS; TUMORS; MANAGEMENT; THERAPY; EPIDEMIOLOGY; CHEMOEMBOLIZATION; DIFFERENTIATION; ENHANCEMENT; NEOPLASMS; SURVIVAL;
D O I
10.21037/hbsn.2019.06.02
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Previous research has demonstrated that specific radiographic criteria, including the presence of calcifications and the enhancement pattern on computed tomography (CT) imaging, correlates with clinicopathologic features and outcomes of patients with gastroenteropancreatic neuroendocrine tumors (NET). We sought to investigate whether these radiographic characteristics were prognostic among patients with neuroendocrine liver metastases (NELM) undergoing surgical resection. Methods: The preoperative contrast-enhanced CT scans of all patients who underwent resection of NELM at a single institution between 2000-2015 were retrospectively reviewed. The presence of calcifications was determined on non-contrast phase imaging. Enhancement on the arterial phase scan was categorized as hyperenhancing, hypoenhancing, or mixed. Relevant clinicopathologic characteristics as well as recurrence-free survival (RFS) and overall survival (OS) were compared between groups. Results: Among 82 patients who underwent resection of NELM, 57 had available data on calcifications while 51 had data available on arterial enhancement patterns. Among all patients, median age was 58 (IQR: 47-63) and the majority were female (N=48, 59.5%). The most common primary tumor locations were pancreas (N=25, 30.5%) and small bowel (N=27, 32.9%). The most commonly performed operations were right hepatectomy (N=29, 35.4%), bisegmentectomy (N=15, 18.3%), and segmentectomy (N=14, 17.1%). Median tumor number was 4 (IQR: 2-9), median Ki-67 was 5% (IQR: 2-10%), and median size of the largest liver metastasis was 4.5 (IQR: 2.8-7.7) cm. Twelve (21%) patients had tumor calcifications. Among patients with and without calcifications there were no differences in demographics, clinicopathologic characteristics, RFS (P=0.772) or OS (P=0.095). Arterial enhancement was hypoenhancing in 23 (45.1%), hyperenhancing in 10 (19.6%), and mixed in 18 (35.3%). Similarly, there were no differences between arterial enhancement groups in demographics, clinicopathologic characteristics, RFS (P=0.618) or OS (P=0.268). Conclusions: Radiographic characteristics on contrast-enhanced CT are not associated with the outcomes of patients undergoing resection of NELM. Future investigations should evaluate the prognostic impact of functional neuroendocrine imaging.
引用
收藏
页码:1 / +
页数:13
相关论文
共 50 条
  • [21] Liver Resection for Neuroendocrine Metastases and the Obligation to Individualize Care
    Blayne A. Sayed
    Alice C. Wei
    Annals of Surgical Oncology, 2018, 25 : 3787 - 3789
  • [22] Benefit of liver resection for hepatic neuroendocrine metastases (NETM)
    Al-Sarira, A. A.
    Sarno, G.
    Jones, R.
    Fenwick, S. W.
    Poston, G. J.
    BRITISH JOURNAL OF SURGERY, 2010, 97 : 91 - 92
  • [23] Surgical Treatment of Neuroendocrine Liver Metastases - Resection, Transplantation
    Frilling, Andrea
    Sotiropoulos, Georgios C.
    Kornasiewicz, Oskar
    Tedeschi, Michele
    Li, Jun
    VISZERALMEDIZIN, 2010, 26 (04): : 253 - 261
  • [24] Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors
    Gaujoux, Sebastien
    Gonen, Mithat
    Tang, Laura
    Klimstra, David
    Brennan, Murray F.
    D'Angelica, Michael
    DeMatteo, Ronald
    Allen, Peter J.
    Jarnagin, William
    Fong, Yuman
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4270 - 4277
  • [25] Outcome following repeat liver resection for colorectal liver metastases
    Nishio, H.
    Hamady, Z. Z. R.
    Malik, H. Z.
    Fenwick, S.
    Prasad, K. Rajendra
    Toogood, G. J.
    Lodge, J. P. A.
    EJSO, 2007, 33 (06): : 729 - 734
  • [26] Clinical Score Predicting Survival Following Resection of Sarcoma Liver Metastases
    Tran, T.
    Norton, J. A.
    Ethun, C. G.
    Grignol, V. P.
    Howard, J. H.
    Abbott, D.
    Kelly, S.
    Tseng, J.
    Roggin, K. K.
    Chouliaras, K.
    Votanopoulos, K.
    Bedi, M.
    Gamblin, T. C.
    Cullinan, D. R.
    Fields, R. C.
    Cardona, K.
    Poultsides, G.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S138 - S138
  • [27] Complications following liver resection for colorectal metastases do not impact on longterm outcome
    Pang, Tony C.
    Spiro, Calista
    Ramacciotti, Tim
    Choi, Julian
    Drummond, Martin
    Sweeney, Edmund
    Samra, Jaswinder S.
    Hugh, Thomas J.
    HPB, 2015, 17 (02) : 185 - 193
  • [28] Safety and Outcomes Following Resection of Colorectal Cancer Liver Metastases in the Era of FOLFOX
    Gur, Ilia
    Wagner, Jesse A.
    Sheppard, Brett C.
    Orloff, Susan L.
    Vaccaro, Gina M.
    Lopez, Charles D.
    Diggs, Brian S.
    Billingsley, Kevin G.
    GASTROENTEROLOGY, 2012, 142 (05) : S1058 - S1058
  • [29] Resection versus transplantation for liver metastases from neuroendocrine tumors
    Coppa, J
    Pulvirenti, A
    Schiavo, M
    Romito, R
    Collini, P
    Di Bartolomeo, M
    Fabbri, A
    Regalia, E
    Mazzaferro, V
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1537 - 1539
  • [30] Neuroendocrine Liver Metastases
    Irene Bargellini
    Caterina Vivaldi
    Giulia Lorenzoni
    Lorenzo Fornaro
    Laura Crocetti
    CardioVascular and Interventional Radiology, 2019, 42 : 1053 - 1054